Lv6
2270 积分 2022-04-19 加入
MA13.11 Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
3天前
已完结
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
3天前
已完结
From Rarity to Reality: Osimertinib’s Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
4天前
已完结
LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)
4天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
5天前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
4个月前
已完结
New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy
4个月前
已完结
PARP inhibitors in ovarian cancer
4个月前
已完结
Evaluation of the effectiveness of ultrasound shear elastography and liver steatometry
7个月前
已完结
Bioactive glass-elicited stem cell-derived extracellular vesicles regulate M2 macrophage polarization and angiogenesis to improve tendon regeneration and functional recovery
9个月前
已完结
皖公网安备34019202002308
